

Chinese startup Hasten Biopharma buys 14 products from Korean firm Celltrion

July 2, 2024 | News

To accelerate expansion in the Pan-Asia area



China-based startup Hasten Biopharmaceutical has successfully acquired the asset rights of 14 branded products across Pan-Asia countries and regions from Celltrion, a Korean biopharmaceutical company.

According to the agreement, Hasten will also own the Marketing Authorisation Holder (MAH) rights for these products in 8 countries and regions, including South Korea, Singapore, Thailand, Australia, China Hong Kong S.A.R.

The deal will enrich Hasten's product pipeline across 8 countries and regions outside mainland China, combined with more qualified global supply chain and a quality management system, which will surely pave the way for access to more high-quality products in the Pan-Asia Area.

As an innovative biopharmaceutical company focused on chronic diseases and critical care area, Hasten will boost its product portfolios through this acquisition with commercial rights to treatments in various chronic disease areas such as hypertension and diabetes. These include Edarbi, Basen, Actos, Blopess and Nesina, spanning across 8 countries and regions in Pan-Asia.

This successful acquisition, facilitated by CBC Group's extensive experience in large-scale cross-border buyouts and platform building, jointly strengthens the development of the global healthcare ecosystem. As the acquisition lays a solid foundation for the company's business expansion in Pan-Asia, Hasten is well positioned to become a leader in the chronic disease ecosystem.